• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What You May Have Missed at the AAD 2023 Annual Meeting

Article

The American Academy of Dermatology (AAD) 2023 Annual Meeting took place last month in New Orleans, Louisiana, and The American Journal of Managed Care® was there to cover the latest news—catch up on what you may have missed.

Here are the top 5 stories from the American Academy of Dermatology (AAD) 2023 Annual Meeting, which took place in New Orleans, Louisiana, from March 17 to 21, 2023.

5. Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

Speakers at AAD 2023 highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.

Read the full article here.

4. Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

A pair of posters showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.

Read the full article here.

3. Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

A panel assembled at AAD 2023 encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.

Read the full article here.

2. Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.

Read the full article here.

1. Experts Herald “Year of the JAK Inhibitor” in Dermatology

A symposium at AAD 2023 convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.

Read the full article here.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
dr peter lio
lisa kottschade
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.